Market research
1349.HK Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd
HK HKD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 7.48
- Dividend yield
- Not available
- Beta
- 0.09
Community
Investor discussion
1 comment
Sign in to join the 1349.HK discussion.
5 years, 5 months ago
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 15.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd's total revenue sank by 16.5% to $338M since the same quarter in the previous year.
Its net income has dropped by 24.6% to $80M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.8% to $75M since the same quarter in the previous year.
Based on the above factors, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd gets an overall score of 2/5.